HOME JOURNALS CONTACT

American Journal of Drug Discovery and Development

Year: 2013 | Volume: 3 | Issue: 3 | Page No.: 188-193
DOI: 10.3923/ajdd.2013.188.193
Methotrexate Plus Prednisolone in Severe Alopecia Areata
A.R. Firooz and D.F. Fouladi

Abstract: Alopecia areata is a chronic disease that may respond poorly to treatment. This study aimed to examine the efficacy of methotrexate plus prednisolone in severe alopecia areata. A total of 10 patients with long-lasting extensive alopecia areata were studied. These patients were recruited from two private dermatological clinics in Tehran (Iran) from September 2011 through December 2012. Oral prednisolone (initial: 0.5 mg kg day-1) and oral methotrexate (5-10 mg week-1) were administered and tapered when a full hair regrowth was achieved. A total regrowth of the terminal hair was regarded “success”. Descriptive analysis was used in this study. Success was achieved in 80% of the patients. Within a mean follow-up of 14.40 months after treatment, relapse occurred in 4 patients (patchy loss = 2, patchy and succeeding diffuse loss = 1, diffuse loss = 1). Relapse resolved using local corticosteroid/dose increase in all 4 patients. Complications were minor and resolved spontaneously. This study showed that oral methotrexate plus oral prednisolone is effective and safe in severe alopecia areata.

Fulltext PDF Fulltext HTML

How to cite this article
A.R. Firooz and D.F. Fouladi, 2013. Methotrexate Plus Prednisolone in Severe Alopecia Areata. American Journal of Drug Discovery and Development, 3: 188-193.

© Science Alert. All Rights Reserved